Latest on Anabolic Agents for Osteoporosis Treatment.
| Autor: | di Filippo L; Institute of Endocrine and Metabolic Sciences, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: difilippo.luigi@hsr.it., Rosen CJ; Center for Clinical and Translational Research, MaineHealth Institute for Research, Scarborough, ME 04074, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Endocrinology and metabolism clinics of North America [Endocrinol Metab Clin North Am] 2024 Dec; Vol. 53 (4), pp. 513-523. Date of Electronic Publication: 2024 Sep 26. |
| DOI: | 10.1016/j.ecl.2024.08.003 |
| Abstrakt: | In the last decades, novel therapeutics with anabolic bone properties have been developed and are currently used in the management of osteoporosis particularly in patients with high-risk of fragility fractures. These drugs include PTH-Related Analogues, teriparatide and abaloparatide, and the anti-sclerostin agent romosozumab, this latter drug currently approved only in female patients. Their efficacies in preventing fragility fractures are widely demonstrated and their potential serious side effects were progressively downgraded, including risk of malignancies in teriparatide- and cardiovascular events in romosozumab-users, respectively. Further data are warranted about their efficacy in glucocorticoids-induces osteoporosis and fracture healings. Competing Interests: Disclosures The authors have nothing to disclose. (Copyright © 2024 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|